Media coverage about Teligent (NASDAQ:TLGT) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teligent earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.8710232193914 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several brokerages have issued reports on TLGT. Zacks Investment Research cut Teligent from a “hold” rating to a “sell” rating in a report on Thursday, May 3rd. Canaccord Genuity set a $4.00 target price on Teligent and gave the company a “hold” rating in a report on Thursday, March 15th. Finally, ValuEngine raised Teligent from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $7.00.
Shares of Teligent stock traded up $0.04 during trading hours on Thursday, hitting $3.08. The company’s stock had a trading volume of 302,902 shares, compared to its average volume of 649,704. Teligent has a twelve month low of $2.43 and a twelve month high of $9.54. The firm has a market cap of $157.86 million, a PE ratio of -16.21 and a beta of 0.77. The company has a quick ratio of 1.69, a current ratio of 2.73 and a debt-to-equity ratio of 3.07.
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.